Gain Therapeutics (NASDAQ:GANX) Trading Up 3.7% – What’s Next?

Gain Therapeutics, Inc. (NASDAQ:GANX) shot up 3.7% on Monday . The stock traded as high as $2.63 and last traded at $2.52. 561,330 shares changed hands during trading, a decline of 29% from the average session volume of 792,922 shares. The stock had previously closed at $2.43.

Wall Street Analysts Forecast Growth

GANX has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a research report on Friday, December 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a report on Monday, December 29th. Finally, Roth Mkm restated a “buy” rating and issued a $10.00 target price on shares of Gain Therapeutics in a report on Friday, December 19th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $8.00.

Gain Therapeutics Stock Up 3.7%

The stock has a market cap of $96.92 million, a P/E ratio of -4.13 and a beta of -0.03. The company has a current ratio of 2.52, a quick ratio of 2.52 and a debt-to-equity ratio of 0.05. The firm’s fifty day moving average is $2.17 and its 200 day moving average is $2.36.

Hedge Funds Weigh In On Gain Therapeutics

Large investors have recently made changes to their positions in the business. Geode Capital Management LLC boosted its stake in Gain Therapeutics by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after purchasing an additional 8,251 shares during the period. Sprott Inc. acquired a new stake in Gain Therapeutics in the 4th quarter valued at approximately $39,000. Benedict Financial Advisors Inc. increased its position in Gain Therapeutics by 55.6% in the 3rd quarter. Benedict Financial Advisors Inc. now owns 35,000 shares of the company’s stock worth $62,000 after buying an additional 12,500 shares during the period. Commonwealth Equity Services LLC bought a new position in Gain Therapeutics in the 4th quarter worth approximately $41,000. Finally, Millennium Management LLC acquired a new position in shares of Gain Therapeutics during the fourth quarter worth approximately $45,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.